Skip to content

In Balans: the (cost-)effectiveness of the In Balans fall prevention training on falls and fall injuries in community-dwelling older adults with an increased risk of falls

In Balans: the (cost-)effectiveness of the In Balans fall prevention training on falls and fall injuries in community-dwelling older adults with an increased risk of falls - In Balans

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON52325
Enrollment
256
Registered
2021-02-10
Start date
2021-08-02
Completion date
Unknown
Last updated
2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ouderdom en valrisico age related decline and fall risk

Interventions

'In Balans' is a fall prevention program of 14 weeks that will be provided by a certified physiotherapist or remedial therapist who has followed a training program to become an 'In Balans' trainer.

Sponsors

Vrije Universiteit
Lead Sponsor

Eligibility

Age
65 Years to 99 Years

Inclusion criteria

Inclusion criteria: 65 years of age or older Increased fall risk according to the fall risk assessment of VeiligheidNL Able to read and understand Dutch Being able to independently take care of themselves (e.g. going to the bathroom, dressing and undressing) and walk 100 meter Classified as non- or pre-frail, based on the frailty criteria according to Fried et al.(body weight (BMI >18.5), grip strength, fatigue (SF-36 vitality score >75), walking speed and physical activity)

Exclusion criteria

Exclusion criteria: Younger than 65 years of age No increased fall risk according to the fall risk assessment of VeiligheidNL Indications of serious cognitive problems (MiniMental State Examination

Design outcomes

Primary

MeasureTime frame
The primary outcome measure is the number of falls (with and without injuries) and will be assessed using fall calendars and monthly telephone calls during the 12-month follow-up.

Secondary

MeasureTime frame
Secondary outcomes (assessed at baseline, at 4 months, and at 12 months) are divided into physical tests and questionnaires. Physical tests: - Balance measured with the 'Performance - Oriented Mobility Assessment - Balance', the 'Four Stage Balance Test' and the 'Timed Up and Go Test' - Mobility measured with the 'Performance - Oriented Mobility Assessment - Mobility' - Muscle strength measured with the 'Hand Grip Strength Test', the 'Timed Chair Stands Test' and the *Short Physical Performance Battery* - Walking speed measured with the '10 Meter Walk Test ' - Aerobic endurance measured with the' 2-minute Step Test ' - Fall risk measured with the' LASA Fall Risk Questionnaire ' - Daily physical activity and gait based on data from movement monitors worn on the lower back for 1 week Questionnaires: - Overall health status assessed by means of the 'Short Form Health Survey - SF-36' and the 'Positive Health Inventory Tool' - Self-determination assessed using the 'Pearlin Mastery Scale' and the 'General Self-Efficacy Scale' - Fall anxiety assessed using the 'Falls Efficacy Scale International - FES-I' - Confidence while walking assessed using the 'Modified Gait Efficacy Scale - mGES' - Frailty assessed using the 'Groningen Frailty Indicator' Demographic characteristics (assessed at baseline and at 12 months): Age, sex, weight, marital status, level of education, use of medication (number), and presence of chronic disease. The frailty status is determined based on the '5 Frailty Indicators': weight (loss), weakness, fatigue, slowness and low physical activity. Moreover, we will ask for the number, of falls, the cause (behavioral, biological, environment), circumstances and consequences of falls (none, small, medium, large) during the 12 month follow-up using the fall calendar and monthly telephone calls In order to determine cost-effectiveness (after 4, 8 and 12 months), we measure: - Quality of life assessed using the 'EuroQol 5D' and th

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)